NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Cadrenal Therapeutics, Inc. (CVKD) Stock Analysis

Cadrenal Therapeutics, Inc. (CVKD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CVKD

$1.22

−$0.06 (−4.69%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CVKD with… →

CVKD Key Statistics

As of Sep 4, 2026
Trading
Open
$1.26
Previous Close
$1.28
Day's Range
1.20–1.30
52-Week Range
1.20–14.64
Volume
177.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.84
Valuation
Market Cap
$4.35M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.69
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$13.24M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
3.57M
1-Year Return
−90.25%
Dividend and dates
Avg Volume
432.75K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CVKD Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−82.01%
2025−53.21%
2024+30.54%
2023−82.04%

As of September 4, 2026.

CVKD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$13.24M—
2024$0.00−$10.65M—
2023$0.00−$8.36M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$13.46M−$13.24M—
2024$0.00—−$10.96M−$10.65M—
2023$0.00—−$7.63M−$8.36M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CVKD Valuation vs Biotechnology Median

Median of 656 stocks
MetricCVKDBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Cadrenal Therapeutics, Inc. (CVKD) at $4.35M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 5.

The most recent close on file for CVKD is $1.22, dated September 4, 2026. That is −$0.06 (−4.69%) against the previous close. The 52-week range on file runs from $1.20 to $14.64. The latest close sits 1.67% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $13.24M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −4.69.

Across the 3 fiscal years on file, revenue moves from $0.00 in 2023 to $0.00 in 2025. Of those 3 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 1.84. Daily returns over the trailing 3 years annualize to a volatility of 100.16%. The trailing one-year price return is −90.25%. Across 3 years the annualized return works out at −54.97%.

Growth & Income

No dividend is on file for CVKD.

2026 is still running; the price is −82.01% year to date. The strongest complete calendar year on file is 2024 at +30.54%; the weakest is 2023 at −82.04%. Of the 3 complete calendar years on file, 1 finished higher.

Peer Comparison

Cadrenal Therapeutics, Inc. (CVKD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cadrenal Therapeutics, Inc. CVKD $4.35M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Cadrenal Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Visit website →